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Matrix metalloproteinase inhibition reduces
intimal hyperplasia in a porcine arteriovenous-graft
model
Joris I. Rotmans, MD,a,b Evelyn Velema, BSc,a Hence J. M. Verhagen, MD, PhD,c Jan D. Blankensteijn,
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Background: The patency of arteriovenous (AV) polytetrafluoroethylene grafts for hemodialysis is impaired by intimal
hyperplasia (IH) at the venous outflow tract. IH mainly consists of vascular smooth muscle cells, fibroblasts, and
extracellular matrix proteins. Because matrix metalloproteinases (MMPs) are enzymes able to degrade extracellular matrix
proteins such as elastin and collagen and also stimulate migration of vascular smooth muscle cells, we hypothesized that
BB2983 (a broad-spectrum MMP inhibitor) could reduce IH in AV grafts.
Methods: In 12 pigs, AV grafts were created bilaterally between the carotid artery and the jugular vein. Six pigs received
the oral MMP inhibitor (MMPi), and six pigs served as a control. Four weeks after AV shunting, the grafts and adjacent
vessels were excised and underwent histologic analysis. Quantification of elastin content was performed on Elastin von
Gieson–stained sections.
Results: At the venous outflow tract, IH was strongly inhibited after MMPi when compared with the control group (1.02
 0.26 mm2 vs 2.14  0.38 mm2; P  .027). The medial area did not differ significantly. In the control group elastin
density decreased compared with nonoperated veins. This decrease was not observed in the MMPi group (nonoperated,
6.3%  0.4%; MMPi, 7.2%  0.7% vs untreated, 3.6%  0.5%; P  .0004). Outward remodeling of the vein was not
influenced by MMP inhibition.
Conclusion: MMPi reduces IH formation at the venous outflow tract of AV grafts in pigs, probably by inhibiting elastin
degradation. These data suggest that MMP inhibitors might be useful for minimizing IH in AV grafts, thus prolonging
patency rates of AV grafts in patients on hemodialysis. (J Vasc Surg 2004;39:432-9.)
Complications at the hemodialysis access site constitute
a major cause of morbidity for patients with end-stage renal
disease who are undergoing chronic hemodialysis. In the
United States approximately 70% of the 250,000 hemodi-
alysis patients use an expanded polytetrafluoroethylene
(ePTFE) graft for permanent vascular access.1 The current
1- and 2-year primary patency rates of these ePTFE grafts
are 50% and 25%, respectively.2 These data are in line with
an incidence rate of complications, which approaches 40%
in patients with ePTFE grafts within the first 6 months. The
failure of hemodialysis access grafts is predominantly due to
the rapid development of an intimal hyperplastic response
in the region of anastomosis between the ePTFE graft and
the vein (ie, venous outflow tract). The intimal hyperplasia
mainly consists of vascular smooth muscle cells (VSMCs)
and extracellular matrix proteins.3-5 Despite coordinated
attempts to solve this clinically important issue, approaches
to reduce graft stenosis have thus far proven unsuccessful.
Matrix metalloproteinases (MMPs) belong to a group
of zinc-dependent proteases and cause breakdown of extra-
cellular matrix proteins such as collagen and elastin, which
is a prerequisite for migration of VSMCs. Flow increase and
vascular injury are potent stimuli for activation of MMP-2
and MMP-9.6,7 These enzymes are able to degrade elastic
fibers in the vessel wall.8,9 Furthermore, recent studies have
emphasized the importance of elastin as a potent regulator
of VSMC proliferation and subsequent neointima forma-
tion after vascular injury.10-12 The beneficial effects of
tissue inhibitor metalloproteinase (TIMP)-213 and
TIMP-3 overexpression14 on intimal hyperplasia after vein
grafting of carotid arteries have underlined the capacity of
MMP inhibition as a potential therapy.
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In the present study, we hypothesized that BB2983, an
oral broad-spectrum MMP inhibitor, could reduce extra-
cellular matrix breakdown and thus reduce the intimal
hyperplastic response at the venous outflow tract of arterio-
venous (AV) ePTFE-grafts in pigs.
MATERIAL AND METHODS
Animals. Twelve female Landrace pigs weighing 52
kg  4.6 kg were studied. ePTFE AV grafts were created
bilaterally between the carotid artery and the internal jug-
ular vein (n  24 grafts). Six pigs received the oral MMP
inhibitor (MMPi), and six pigs served as controls. All
animals were killed 28 days after surgery. The study proto-
col was approved by the Ethical Committee on Animal
Experimentation of the University Medical Center, Utre-
cht, and animal care followed established guidelines.15
Anesthesia. Before operation and termination, the an-
imals were deprived of food and water overnight and pre-
medicated with intramuscular ketamine hydrochloride 10
mg/kg, midazolam 0.4 mg/kg, atropin 0.5 mg, and intra-
venous thiopental sodium 4 mg/kg. They were then intu-
bated and ventilated with a mixture of O2 and air (1:2) and
halothane (0.6%). An ear vein was used for continuous
administration of 0.3 mg/kg per hour midazolam and 2.5
g/kg per hour sufentanil.
Operative procedures. Starting 6 days before the op-
eration, the pigs received acetylsalicylic acid 80 mg/dd.
Clopidogrel 225 mg was given 1 day prior to the operation
and was continued at a dose of 75 mg/d until termination.
Through a longitudinal incision in the midline of the neck,
the common carotid artery and the internal jugular vein
were dissected bilaterally. Heparin 100 IU/kg intrave-
nously was given before manipulation of the vessels. All the
AV grafts were created by the same experienced vascular
surgeon (H.V.). The artery was clamped with atraumatic
clamps, and an arteriotomy was made (8 mm). An end-to-
side anastomosis was created at an angle of 45° by use of a
continuous suture of 8-0 polypropylene (Prolene; Ethicon,
Somerville, NJ). All ringed ePTFE grafts were 5 mm in
diameter and 7 cm in length (W. L. Gore and Associates,
Flagstaff, Ariz). The venous anastomosis was created in a
similar fashion (Fig 1). The blood flow through the artery
(proximal and distal to the anastomosis) and vein (proximal
and distal) was measured several minutes after completing
the anastomosis with a 4-mm perivascular flow probe
(Transonic Systems, Maastricht, The Netherlands). Graft
flow was calculated as flow of the proximal carotid artery
minus the flow of the distal artery. The external diameter of
the jugular vein was measured with a microscope with an
internal raster (40 magnification), 1 cm from the anasto-
mosis (proximal and distal).
After 4 weeks, pigs were anesthetized as described
previously. After we measured flow, the animals were killed.
Because of extensive formation of granulation tissue, we
refrained from measuring the external diameter of the veins
in view of the risk of tearing. The proximal carotid artery
supplying the graft was cannulated and ligated beyond the
cannula. The grafts and adjacent vessels were perfused with
saline for 3 minutes. Subsequently, the grafts were perfused
with formalin at physiologic pressure (100 mmHg). Two
minutes later, both sides of the arteries and the veins were
ligated to pressure-fixate the vessels. Grafts and adjacent
vessels were then excised and immersed in formalin for a
minimum of 24 hours.
MMP activity. To study MMP activity in our model,
portions of the grafted jugular vein of control pigs, 3 cm
proximal and distal to the anastomosis, were fresh frozen in
liquid nitrogen at the time of death. The femoral vein
served as an unoperated control. Zymography was per-
formed on each sample with electrophoresis through a 10%
sodium dodecyl sulfatepolyacrylamide gel electrophoresis
(SDS-PAGE) gel containing 1% gelatin, as described
previously.7
MMP inhibition. The oral nonspecific synthetic
MMP inhibitor BB2893 was supplied by British Biotech
Pharmaceuticals Limited, Oxford, UK. This drug inhibits,
in the nanomolar range, all known classes of MMPs. Pigs in
the MMP inhibitor group were treated until death with 10
mg/kg given orally twice a day, starting 1 day after the
operation. An unpublished dosimetry study in Landrace
pigs in our lab established that a dose of 10 mg/kg of the
comparable compound BB2516 twice a day would give
exposure of 100 to 200 ng/mL plasma, a concentration
which has been shown to be effective in animal models of
cancer.
To demonstrate bioavalability of the MMP inhibitor in
the vascular tissue of the treated pigs, a collagenase activity
assay was performed (Molecular Probes, The Netherlands).
Thirty fresh-frozen sections (5 m each) of the femoral
arteries of four pigs were dissolved in dimethyl sulfoxide
(DMSO). These extracts were tested on their ability to
inhibit collagenase activity. As a positive control, BB2983
was diluted in DMSO. Collagen from bovine skin (100
g/mL) was diluted in reaction buffer and added to the
different tissue extracts. Next, collagenase type IV (0.5
U/mL) was added to start the proteolytic reaction.
Fig 1. ePTFE graft between the carotid artery and the internal
jugular vein.
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Tissue preparation and morphometric analysis.
The fixated veins were cut in 5-mm blocks and embedded
in paraffin. Sections (5 m thick) were prepared of the vein
1 cm proximal and distal to the anastomosis and at the
center of the anastomosis (Fig 2). To minimize the variabil-
ity of sectioning the anastomosis, we selected the sections
in which half of the circumference is composed of the
ePTFE graft and the other half of the recipient vein. (Fig 2,
B). The standardized angle of the anastomosis (45°) was
used to be sure that sections were cut perpendicular to the
vein.
For morphometric analysis, sections were stained for
general morphology (Elastin von Gieson) and collagen
(picro-Sirius red). All sections were stained by one techni-
cian, in three sessions. Although the intensity of the stain-
ing can slightly differ between sessions, the area measure-
ments could be performed reliably because, above a certain
threshold, they do not depend on the intensity of the
stainings.
Area measurements were performed on captured im-
ages obtained with a color camera attached to a light
microscope with the use of computer-assisted morphome-
try. The area and thickness of the intima and media were
manually traced by Elastin von Gieson–stained section. The
intima was defined as the area above the internal elastic
lamina. Interrupted elastic laminae were connected by
manual tracing. The intima could be easily distinguished
from the media by the disorganized structure of intimal
cells. Thrombus formation was discriminated from intimal
hyperplasia by using hematoxylin-eosin– and Elastin von
Gieson–stained sections.
In the sections of the venous anastomosis, two parts of
the intima area were distinguished: (1) the intima covering
the graft (shoulder region) and (2) the intima located at the
venous part of the anastomosis (cushioning region) (Fig 2,
B).
The venous diameter was traced in the sections that
were located 1 cm proximal and distal to the anastomosis.
This diameter is a valid measure for outward remodeling
because the veins were pressure-fixated.
Quantification of elastin content was performed on
Elastin von Gieson–stained sections of the grafted vein, 1
cm proximal and distal to the anastomosis and at the center
of the venous anastomosis. Only the elastin-positive pixels
of captured images were selected by using a color threshold
mask focused on the black pixels. Elastin area was expressed
as a percentage of the vessel wall by dividing the elastin-
positive pixels by the medial and adventitial cross-sectional
area.
Quantification of collagen content of the grafted veins
was performed by using picro-Sirius red-stained sections
and digital image microscopy with circularly polarized light
as described by Perree et al.16 Collagen density was calcu-
lated by dividing the collagen content by the vessel wall
cross-sectional area.
Statistical evaluation. Data are presented as mean 
SEM. SPSS 11.0 (Chicago, Ill) was used for all statistical
calculations. We performed the Mann-Whitney test to as-
certain the significance of differences among the two
groups. P  .05 was considered significant.
RESULTS
Characteristics of animal model
All grafts except one in the MMP inhibitor group were
patent at the time of harvest. Patent grafts (n  23) were
included for further analysis. The proximal vein of the
occluded graft was completely thrombosed, most likely
because of local infection. The increase in weight during
follow-up was 10.3  1.6 kg in the MMPi-treated group
and 8.6  0.9 kg in the control group. None of the pigs
showed side effects like diarrhea or other signs of toxicity.
No differences in wound healing were observed between
the groups.
Baseline flow through the jugular vein was 42  6
mL/min. AV graft implantation resulted in a graft flow of
829  71 mL/min (proximal vein, 448  55 mL/min;
distal vein, 381 42 mL/min). On day 28, flow measure-
ments of the grafts revealed no significant differences be-
tween the controls and BB2983-treated animals (961 91
mL/min vs 956  96 mL/min, respectively).
Gelatin zymographic analysis of protein extracts from
the jugular vein revealed three bands of metalloproteinase
activity with molecular weights of approximately 68, 72,
and 95 kDa, corresponding with pro-MMP2, active
MMP-2, and MMP-9, respectively. At 28 days, protein
Intima and media areas of Elastin von Gieson–stained
sections obtained from the venous anastomosis
Venous anastomosis Control pigs
BB2983-
treated pigs P
Total intima area 2.14  0.38 1.02  0.26 0.027
Shoulder region 1.08  0.23 0.32  0.12 0.009
Cushioning region 1.07  0.31 0.70  0.23 0.57
Media area 1.71  0.22 2.10  0.38 0.45
Intima/media ratio 1.32  0.21 0.51  0.11 0.004
Intima and media values are expressed in square millimeters and are the
mean area  SEM.
Fig 2. A, Frontal view. V-1 is the jugular vein located 1 cm
proximal of the anastomosis. V-2 is the center of the anastomosis.
V-3 is the jugular vein 1 cm distal of the anastomosis. B, Cross
section of the anastomosis (V-2). Intimal hyperplasia is situated at
the facing vein (1  cushioning region) and at the edge of the
ePTFE graft (2  shoulder region).
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extracts from the grafted jugular veins revealed augmented
gelatinolytic activity of all three bands, compared with the
femoral veins (Fig 3).
Morphometric analysis
Intima and media areas. At 4 weeks, vein grafts in
control animals showed extensive intimal hyperplasia. In
the untreated group, more intimal hyperplasia was formed
compared with the MMPi-treated animals (Fig 4, A-B).
–Smooth muscle actin staining confirmed that the intimal
hyperplasia predominantly consisted of VSMCs (Fig 4, E).
Data of the intima and media area measurements are
summarized (Table). A 53% reduction in intima formation
at the venous anastomosis was achieved in the group
treated with BB2983 for 28 days. The reduction of the
intima covering the graft (70%) and the facing vein (34%)
both contributed to this inhibitory effect of BB2983. At 1
cm proximal and distal to the anastomosis, the intimal and
medial areas did not differ significantly between the
BB2983-treated animals and the control group.
Elastin area and collagen density. Densitometric
analysis of elastin area and collagen density of the grafted
veins is shown in Fig 5. At all three locations the elastin area
was larger in the BB2983-treated group, compared with
the untreated pigs (anastomosis, 7.2%  0.7% vs 3.6% 
0.5%; P  .001; proximal, 7.0%  0.7% vs 4.9%  1.1%; P
 .04; distal, 6.7%  0.7% vs 3.8%  0.4%; P  .03,
respectively). Linear regression analysis showed a signifi-
cant relationship between the elastin area and intimal hy-
perplasia (IH) at the venous anastomosis (R  0.47, P
.02). Representative Elastin von Gieson–stained sections at
large magnification are shown in Fig 4, C-D,; the elastic
fibers are black.
Collagen density was not significantly different be-
tween control and BB2983-treated animals, except for a
modest difference in the distal vein (26.7  3.3 gray
values/mm2 vs 36.7  4.3 gray values/mm2, respectively,
P  .05). An example of a picro-Sirius–stained section is
shown in Fig 4, F.
Venous diameters. Immediately after creation of the
AV graft, the mean external diameter of the proximal and
distal jugular vein did not differ among control and
BB2983-treated animals (proximal, 3.91  0.29 mm vs
3.37  0.25 mm; P .26; distal, 3.90  0.21 mm vs 3.94
 0.22 mm; P .42, respectively). At 28 days, histologi-
cally determined venous diameters did not differ between
the untreated pigs and the BB2983-treated pigs. (proximal,
4.15  0.37 mm vs 3.61  0.40; distal, 5.06  0.55 vs
5.37  0.44 mm, respectively).
MMP inhibition in tissue extracts. A 30% reduction
in collagenase activity was observed in tissue extracts of the
arteries treated with MMP inhibitor (n  2), when com-
pared with control arteries, implying that MMP inhibitory
compound is actually present within arterial tissue (un-
treated, 195 arbitrary units  9 [SEM] vs MMPi-treated,
137 arbitrary units  11 [SEM]; BB2983 in DMSO 1
g/mL, 120 arbitrary units  8).
DISCUSSION
In the present study we show that neointimal formation
at the venous outflow tract of ePTFE AV grafts is signifi-
cantly reduced after MMP inhibition. The elastin content
in operated vessels was preserved in the MMPi group,
whereas a sharp decrease in elastin content was observed in
the control group. Finally, venous outward remodeling was
not negatively influenced by MMP inhibition.
MMP inhibition and venous intimal hyperpla-
sia. MMPs are key enzymes during rebuilding of the vessel
wall matrix, which occurs in the process of vascular remod-
eling.17,18 Surgical preparation of the venous wall19 and
flow changes (ie, shear stress alterations),20-23 both charac-
teristics of the AV grafting procedure, are potent stimuli for
increasing MMP activity.
Because MMPi has been shown to decrease matrix
breakdown and VSMC migration,24-26 MMPi can be ex-
pected to exert beneficial effects on intimal hyperplasia,
particularly in an ePTFE AV-graft model. Indeed, in the
present study we show a reduction in intimal hyperplasia at
the venous outflow tract in a porcine AV-graft model.
These findings concur with previous data, showing a reduc-
tion of neointimal formation in grafted veins during TIMP
overexpression.13,14,27 In the study of Porter et al,27 doxy-
cycline reduced intima formation in cultured human saphe-
nous veins by inhibiting MMP-9 activity. Those studies
Fig 3. Representative gelatin zymographic analysis of protein extracts obtained from jugular and femoral veins of
control pigs at 28 days. Lane one, recombinant MMP-9; lane two, recombinant MMP-2; lane three, tissue extract
femoral vein; lane four, tissue extract left jugular vein at 28 days; lane five, tissue extract right jugular vein at 28 days.
Note, the molecular weights of porcine MMP-2 and MMP-9 are slightly smaller then the molecular weights of human
recombinant MMP-2 and MMP-9.
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consistently show a beneficial effect of MMP inhibition on
venous intimal hyperplasia.
The intimal proliferation at the venous outflow tract of
AV grafts has characteristic localizations, both at the edge
of the ePTFE graft (shoulder region) and at the facing vein
(cushioning region). Whereas stretch injury is thought to
be of major importance for the proliferation at the shoulder
region, the absence of shear (no/low-flow zone) may be of
particular relevance at the cushioning region.28-30 Interest-
ingly, we observed that BB2983 inhibits intimal formation
in both these regions.
The inhibitory effect of the MMPi on intimal hyperpla-
sia was limited to the anastomotic region (V-2 in Fig 2). A
possible explanation for this local effect might be that the
stimuli for MMP activation (ie, vascular injury and flow
changes) differ among regions. In this respect, it should be
noted that the tissue extracts for zymography were not
obtained from the center of the anastomosis.
Fig 4. A, Representative Elastin von Gieson-stained 5-m section of a venous anastomosis of a BB2983-treated pig
and an untreated pig (B) (original magnification, 12.5). C, Detail of Elastin von Gieson-stained section of a
BB2983-treated pig and an untreated pig (D), showing elastic fibers in black (original magnification, 100). E, Detail
of -actin smooth muscle cell-stained section (original magnification, 200). F, Picro-Sirius-stained section of venous
anastomosis, visualized with polarized light (original magnification, 12.5).
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MMP inhibition and elastin area. A higher elastin
density in the vessel wall was found in the animals treated
with MMP inhibitor. These results are in accordance with
the study of Forough et al31 that demonstrated elastin
accumulation after endogenous MMPi by TIMP-1 overex-
pression. Interestingly, perivascular release of elastase after
venous and arterial injury limits neointimal hyperplasia by
directionally guiding VSMC responses, implying a direct
inhibitory effect of the intact elastic lamina on neointima
formation.32,33
The results of the present study confirm an important
role for MMPs in elastin breakdown occurring after vascu-
lar injury. The inverse correlation between elastin content
and intimal hyperplasia indicates that reduced elastic fiber
breakdown in the MMPi animals may have contributed to a
decreased neointimal area. Besides the guiding function of
elastin in VSMC responses, this inverted relationship might
also be explained by the ability of MMPs to attract and
activate inflammatory cells, which has been described in
abdominal aortic aneurysms.34 However, the lack of effect
of MMP inhibition on macrophage infiltration in bal-
loon-dilated porcine arteries does not support this hy-
pothesis.35
MMP inhibition and collagen content. In contrast
to the elastin density, no difference in collagen content was
observed between the groups. Different studies have em-
phasized the role of MMPs and MMP inhibitors in collagen
turnover after vascular injury. MMPs are not only involved
in collagen degradation, but they also affect collagen syn-
thesis and cross-linking.36-38 Collagen synthesis and colla-
gen breakdown are both up-regulated after vascular inju-
ry.36 Inhibition of collagen degradation by the MMP
inhibitor might decrease collagen synthesis by a feedback
loop.39,40 Furthermore, the MMP inhibitor could inhibit
the shedding of receptors, such as tumor necrosis factor 
(TNF-),41 that affect collagen synthesis.42 When both
collagen degradation and synthesis are reduced, then total
collagen content does not change. The net effect of MMPi
on collagen content may also vary between different MMP
inhibitors and animal models.
In addition to the influence on matrix composition of
MMPi, increased apoptosis of VSMCs, causing a reduction
Fig 5. A, Densitometric analysis of elastin area of grafted veins from untreated pigs (n 12) and BB2983-treated pigs
(n  11). Control veins are jugular veins of pigs without AV graft. B, Densitometric analysis of collagen density of
grafted veins from untreated pigs (n  12) and BB2983-treated pigs (n  11).
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in intimal VSMCs, should be considered. However, MMP
inhibition might also result in decreased apoptosis of
VSMCs, because apoptosis is regulated by cell-matrix inter-
actions.43 Furthermore, MMPs may also directly promote
apoptosis by releasing both soluble Fas ligand44 and mem-
brane-bound TNF- from cells.45
In our study, one infected graft was observed in the
MMPi-treated group. The question remains whether MMP
inhibition reduced graft incorporation, making it more
susceptible to infection and thus graft thrombosis. The role
of MMPs in wound and anastomotic healing has been
investigated by Balcom et al. 46 In that study, MMP inhi-
bition did not impair wound or enteric healing in a rat
model of laparotomy and small bowel resection.46
On the basis of our data, we cannot exclude that MMP
inhibition increases the risk of graft infection. However, the
limited incidence of graft infection does not support such
causal relation.
Future clinical application. The first available oral
MMP inhibitors have entered clinical trials in the field of
oncology.52 With long-term treatment, reversible joint and
muscle pain were reported frequently. However, it is likely
that more selective MMP inhibitors, which are currently
being manufactured and tested, will have fewer side effects.
These specific MMP inhibitors will probably result in more
knowledge of the role of MMPs in cardiovascular disease,
with subsequent accurate targeting of the disease and re-
duction of possible side effects.
STUDY LIMITATIONS
Bendeck et al47 reported that the decrease in VSMC
migration after MMPi in a model of arterial injury is fol-
lowed by an increase in VSMC replication and a subsequent
“catch up” of lesion size. On the basis of the results of our
study, we cannot exclude the occurrence of this catch-up
phenomenon. However, this phenomenon is described to
occur from 14 days after intervention, whereas our study
continued up to a later time point of 4 weeks.
Venous outward remodeling is essential for adequate
maturation of the vein distal to the graft. Different studies
emphasized the role of MMP-2 in flow-mediated arterial
enlargement.6,48 Hu et al13 reported a significant reduction
of the venous diameter after endogenous MMPi on
TIMP-2 gene transfer after 8 weeks. In our study, venous
outward remodeling was not impaired after 4 weeks of
MMP inhibition. Therefore, we cannot exclude that our
follow-up period of 4 weeks has been too short to detect a
negative effect of MMP inhibition on venous outward
remodeling.
Cardiovascular disease is the major cause of death in
patients with end-stage renal disease.49 A multitude of risk
factors, including the uremic milieu and perhaps the hemo-
dialysis procedure itself, is likely to contribute to premature
cardiovascular diseases.50,51 These risk factors, not present
in our model, might also play a role in AV-graft failure in
hemodialysis patients.
CONCLUSIONS
MMP inhibition reduces neointimal formation at the
venous outflow tract of AV grafts in pigs. The protective
effect of MMPi on elastic fiber breakdown may have con-
tributed to the decreased neointimal area. These data sug-
gest that MMP inhibitors might be useful for minimizing
intimal hyperplasia in human AV grafts, thus prolonging
patency rates of AV grafts in patients receiving dialysis.
Machiel Nagtegaal is acknowledged for excellent assis-
tance with the pathology work-up.
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